Companies / Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc.
Nasdaq: ELVNCIK 1672619BURLINGAME, CA
Insider flow · last 90 daysNet sells $51.68M
Financials
Ownership
73.3M shares outstanding · as of Jul 28, 2026
Ownership
| Insiders | 0.07% | 47,647 |
| 10%+ / strategic | 8.95% | 6,555,102 |
| Institutions | 77.21% | 56,575,118 |
| Public float | 13.77% | 10,092,894 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 14
View all →| Insider | % of shares | Shares |
|---|---|---|
Orbimed Advisors LLC10% owner | 8.95% | 6,555,102 |
Lyssikatos Joseph PFormerCHIEF SCIENTIFIC OFFICER | 1.04% | 758,938 |
Patel AnishFormerCHIEF OPERATING OFFICER | 0.32% | 235,011 |
Hohl BenjaminFormerCHIEF FINANCIAL OFFICER | 0.07% | 51,000 |
Collins Helen LouiseCHIEF MEDICAL OFFICER | 0.03% | 25,000 |
Heyman Richard A.Director | 0.03% | 22,647 |
Ballal Rahul D.Director | — | — |
Bauer JakeDirector | — | — |
Derynck Mika KDirector | — | — |
Garland J. ScottDirector | — | — |
Institutional holders 143
View all →| Holder | Value | % of shares |
|---|---|---|
| $312.01M | 10.86% | |
| $221.25M | 5.95% | |
| $109.46M | 9.70% | |
| $72.27M | 6.40% | |
| $61.59M | 1.66% | |
| $58.98M | 5.23% | |
| $57.16M | 5.07% | |
| $54.11M | 4.80% | |
| $50.18M | 1.75% | |
| $49.69M | 4.40% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Trim | Common Stock | $-65.10M | -1.7M -99.34% | 11,000 0.02% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $37.88M | +746K +20.66% | 4,359,704 5.95% of shares | medium |
| Q1 2026 as of | Baker Bros. Advisors LP 13F manager | Add | Common Stock | $24.84M | +634K +233.52% | 905,191 1.24% of shares | medium |
| Q2 2025 as of | Boxer Capital Management, LLC 13F manager | Exit | Common Stock | $-13.21M | -671K -100.00% | 0 | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | Common Stock | $12.15M | +310K | 310,025 0.42% of shares | medium |
| Q1 2026 as of | AllianceBernstein L.P. 13F manager | Add | Common Stock | $11.32M | +735K +1995.24% | 771,885 1.05% of shares | medium |
| Q2 2026 as of | TimesSquare Capital Management, LLC 13F manager | Add | Common Stock | $10.98M | +216K +480.76% | 261,344 0.36% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $8.16M | +161K +15.27% | 1,213,616 1.66% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vestal Point Capital, LP | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ELVN | Common Stock | 29337E102 |